SkyePharma

Executive Summary

SkyePharma is a French independent CDMO specializing in complex oral solid dosage forms, including highly potent APIs (HPAPIs), orphan drugs, and innovative drug delivery technologies. Operating from a cGMP facility in Lyon, the company provides integrated services from early-stage development through commercial manufacturing and packaging. With over 30 years of experience, SkyePharma has established itself as a trusted partner for challenging projects that require specialized handling and expertise. The company serves a mix of large pharma and emerging biotech clients, capitalizing on the growing demand for outsourced development and manufacturing of high-potency and orphan drugs. The CDMO market continues to expand, driven by increasing R&D outsourcing and the need for specialized capabilities. SkyePharma is well-positioned to benefit from these trends, given its focus on niche, high-value segments. The company's recent investments in capacity and technology, along with its strong regulatory track record, support its growth trajectory. As a private entity, SkyePharma may consider strategic partnerships or eventual IPO to fuel further expansion. Key challenges include competition from larger CDMOs and the need to maintain high quality and compliance standards.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new manufacturing capacity expansion60% success
• Q4 2026Strategic partnership or contract win with top-20 pharma for HPAPI program40% success
• Q2 2026Successful FDA/EMA inspection outcome for Lyon facility85% success